Different Presentation and Outcomes in the Surgical Treatment of Advanced MRONJ in Oncological and Nononcological Patients Taking or Not Corticosteroid Therapy

Table 1

Drugs used with indications: metastatic cancer, multiple myeloma, OS (osteoporosis), AR (rheumatoid arthritis), and CS (Cushing syndrome); route of administration: endovenous (e.v.), intramuscular (i.m.), subcutaneous (s.c.), and oral administrations (o.a.). Doses and time on setting MRONJ.

(a) Oncologic patients

Therapy	Patients	Indications	Type of administration	Dose/frequency	Time on setting of MRONJ
Zoledronate	12	Metastatic cancer	e.v.	4 mg/3-4 weeks	15-20 months
Pamidronate	8	Metastatic cancer	e.v.	90 mg/every 30 days	24-32 months
Ibandronate	6	Metastatic cancer	e.v.	6 mg/3-4 weeks	22-30 months
Ibandronate	3	Metastatic cancer	o.a.	50 mg/day	27-34 months
Multiple types of BPS	3	Multiple myeloma	o.a., i.m., o.a.	Risedronate 5 mg/day; Clodronate 800 mg/day; Alendronate 10 mg/day	12-18 months
Tot.	32

(b) Nononcologic patients

Therapy	Patients	Indications	Type of administration	Dose/frequency	Time on setting of MRONJ
Clodronate	6	OS	e.v.	300 mg/day every 3 weeks	38-72 months
Alendronate	13	OS	o.a.	70 mg/week	50-76 months
Denosumab	13	OS/AR/CS	s.c.	60 mg/6 months	20-30 months
Tot.	32